{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:18:28Z","timestamp":1790806708694,"version":"4.1.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2019,9,29]],"date-time":"2019-09-29T00:00:00Z","timestamp":1569715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In April 2015, in collaboration with the US Centers for Disease Control and Prevention and Gilead Sciences, the country of Georgia embarked on the world\u2019s first hepatitis C elimination program. We aimed to assess progress toward elimination targets 3 years after the start of the elimination program.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We constructed a hepatitis C virus (HCV) care cascade for adults in Georgia, based on the estimated 150 000 persons aged \u226518 years with active HCV infection. All patients who were screened or entered the treatment program during April 2015\u2013March 2018 were included in the analysis. Data on the number of persons screened for HCV were extracted from the national HCV screening database. For the treatment component, we utilized data from the Georgia National HCV treatment program database. Available treatment options included sofosbuvir and ledipasvir\/sofosbuvir\u2013based regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Since April 2015, a cumulative 974 817 adults were screened for HCV antibodies; 86 624 persons tested positive, of whom 61 925 underwent HCV confirmatory testing. Among the estimated 150 000 adults living with chronic hepatitis C in Georgia, 52 856 (35.1%) were diagnosed, 45 334 (30.2%) initiated treatment with direct-acting antivirals, and 29 090 (19.4%) achieved a sustained virologic response (SVR). Overall, 37 256 persons were eligible for SVR assessment; of these, only 29 620 (79.5%) returned for evaluation. The SVR rate was 98.2% (29 090\/29 620) in the per-protocol analysis and 78.1% (29 090\/37 256) in the intent-to-treat analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Georgia has made substantial progress in the path toward eliminating hepatitis C. Scaling up of testing and diagnosis, along with effective linkage to treatment services, is needed to achieve the goal of elimination.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciz956","type":"journal-article","created":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T07:27:13Z","timestamp":1569482833000},"page":"1263-1268","source":"Crossref","is-referenced-by-count":25,"title":["Three Years of Progress Toward Achieving Hepatitis C Elimination in the Country of Georgia, April 2015\u2013March 2018"],"prefix":"10.1093","volume":"71","author":[{"given":"Tengiz","family":"Tsertsvadze","sequence":"first","affiliation":[{"name":"Infectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi, Georgia"},{"name":"Ivane Javakhishvili Tbilisi State University, Tbilisi, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amiran","family":"Gamkrelidze","sequence":"additional","affiliation":[{"name":"National Center for Disease Control and Public Health, Tbilisi, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikoloz","family":"Chkhartishvili","sequence":"additional","affiliation":[{"name":"Infectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akaki","family":"Abutidze","sequence":"additional","affiliation":[{"name":"Infectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lali","family":"Sharvadze","sequence":"additional","affiliation":[{"name":"Ivane Javakhishvili Tbilisi State University, Tbilisi, Georgia"},{"name":"Hepatology Clinic HEPA, Tbilisi, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vakhtang","family":"Kerashvili","sequence":"additional","affiliation":[{"name":"Infectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maia","family":"Butsashvili","sequence":"additional","affiliation":[{"name":"Health Research Union, Tbilisi, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Metreveli","sequence":"additional","affiliation":[{"name":"Medical Center Mrcheveli, Tbilisi, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lia","family":"Gvinjilia","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention Foundation, Tbilisi, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun","family":"Shadaker","sequence":"additional","affiliation":[{"name":"National Center for HIV, Hepatitis, STD, and TB Prevention, Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muazzam","family":"Nasrullah","sequence":"additional","affiliation":[{"name":"National Center for HIV, Hepatitis, STD, and TB Prevention, Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterine","family":"Adamia","sequence":"additional","affiliation":[{"name":"Ministry of Labour, Health and Social Affairs of Georgia, Tbilisi, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Zeuzem","sequence":"additional","affiliation":[{"name":"Goethe University Hospital, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nezam","family":"Afdhal","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center Liver Center, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Arora","sequence":"additional","affiliation":[{"name":"University of New Mexico, Albuquerque, New Mexico, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla","family":"Thornton","sequence":"additional","affiliation":[{"name":"University of New Mexico, Albuquerque, New Mexico, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Skaggs","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention South Caucasus Office, Tbilisi, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tinatin","family":"Kuchuloria","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention South Caucasus Office, Tbilisi, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maia","family":"Lagvilava","sequence":"additional","affiliation":[{"name":"Ministry of Labour, Health and Social Affairs of Georgia, Tbilisi, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sergeenko","sequence":"additional","affiliation":[{"name":"Ministry of Labour, Health and Social Affairs of Georgia, Tbilisi, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Averhoff","sequence":"additional","affiliation":[{"name":"National Center for HIV, Hepatitis, STD, and TB Prevention, Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,9,29]]},"reference":[{"key":"2020082200571000700_CIT0001","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/j.jhep.2015.02.006","article-title":"From non-A, non-B hepatitis to hepatitis C virus cure","volume":"62","author":"Pawlotsky","year":"2015","journal-title":"J Hepatol"},{"key":"2020082200571000700_CIT0002","volume-title":"Global health sector strategy on viral hepatitis 2016\u20132021","author":"World Health Organization","year":"2016"},{"key":"2020082200571000700_CIT0003","article-title":"Global progress towards hepatitis elimination\u2014an update.","author":"Bulterys","year":"2019"},{"key":"2020082200571000700_CIT0004","author":"CDA Foundation"},{"key":"2020082200571000700_CIT0005","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S2468-1253(18)30270-X","article-title":"Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology and Hepatology Commission","volume":"4","author":"Cooke","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2020082200571000700_CIT0006","doi-asserted-by":"crossref","first-page":"e25050","DOI":"10.1002\/jia2.25050","article-title":"How far are we from viral hepatitis elimination service coverage targets?","volume":"21","author":"Hutin","year":"2018","journal-title":"J Int AIDS Soc"},{"key":"2020082200571000700_CIT0007","author":"World Bank"},{"key":"2020082200571000700_CIT0008","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s11524-006-9032-y","article-title":"Prevalence of hepatitis C, HIV, and risk behaviors for blood-borne infections: a population-based survey of the adult population of T\u2019bilisi, Republic of Georgia","volume":"83","author":"Stvilia","year":"2006","journal-title":"J Urban Health"},{"key":"2020082200571000700_CIT0009","doi-asserted-by":"crossref","first-page":"753","DOI":"10.15585\/mmwr.mm6428a2","article-title":"Launch of a nationwide hepatitis C elimination program\u2014Georgia, April 2015","volume":"64","author":"Mitruka","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2020082200571000700_CIT0010","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.21669","article-title":"FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and Fibrotest","volume":"46","author":"Vallet-Pichard","year":"2007","journal-title":"Hepatology"},{"key":"2020082200571000700_CIT0011","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hep.20506","article-title":"Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C","volume":"41","author":"Ziol","year":"2005","journal-title":"Hepatology"},{"key":"2020082200571000700_CIT0012","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.15585\/mmwr.mm6541a2","article-title":"National progress toward hepatitis C elimination\u2014Georgia, 2015-2016","volume":"65","author":"Gvinjilia","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2020082200571000700_CIT0013","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1186\/s12889-019-6784-3","article-title":"Hepatitis C prevalence and risk factors in Georgia, 2015: setting a baseline for elimination","volume":"19","author":"Hagan","year":"2019","journal-title":"BMC Public Health"},{"key":"2020082200571000700_CIT0014","doi-asserted-by":"crossref","first-page":"S142","DOI":"10.1016\/S0168-8278(18)30500-2","article-title":"Interim evaluation and projected impact of the hepatitis C virus elimination program in Georgia","volume":"68","author":"Walker","year":"2018","journal-title":"J Hepatol"},{"key":"2020082200571000700_CIT0015","volume-title":"Eliminating viral hepatitis: the investment case","author":"Pedrana","year":"2018"},{"key":"2020082200571000700_CIT0016","doi-asserted-by":"crossref","first-page":"e337","DOI":"10.1016\/S0618-8278(19)30659-0","article-title":"Iceland may already have reached the WHO 2030 targets for diagnosis and treatment of hepatitis C virus infection: results from the treatment as prevention for hepatitis C (Trap HepC) program","volume":"70","author":"Olafsson","year":"2019","journal-title":"J Hepatol"},{"key":"2020082200571000700_CIT0017","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/apt.15210","article-title":"Treatment access is only the first step to hepatitis C elimination: experience of universal anti-viral treatment access in Australia","volume":"49","author":"Doyle","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2020082200571000700_CIT0018","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S2468-1253(18)30268-1","article-title":"One step closer to elimination of hepatitis C in Egypt","volume":"3","author":"Esmat","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2020082200571000700_CIT0019","doi-asserted-by":"crossref","first-page":"773","DOI":"10.15585\/mmwr.mm6629a2","article-title":"The role of screening and treatment in national progress toward hepatitis C elimination\u2014Georgia, 2015\u20132016","volume":"66","author":"Nasrullah","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2020082200571000700_CIT0020","volume-title":"HIV, viral hepatitis and sexually transmissible infections in Australia: annual surveillance report 2018","author":"Kirby Institute","year":"2018"},{"key":"2020082200571000700_CIT0021","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ebiom.2016.08.035","article-title":"The population level cascade of care for hepatitis C in British Columbia, Canada: the BC Hepatitis Testers Cohort (BC-HTC)","volume":"12","author":"Janjua","year":"2016","journal-title":"EBioMedicine"},{"key":"2020082200571000700_CIT0022","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2105\/AJPH.2015.302927","article-title":"Cascade of care for hepatitis C virus infection within the US Veterans Health Administration","volume":"106","author":"Maier","year":"2016","journal-title":"Am J Public Health"},{"key":"2020082200571000700_CIT0023","volume-title":"Monitoring hepatitis C treatment uptake in Australia (issue 9)","author":"Kirby Institute","year":"2018"},{"key":"2020082200571000700_CIT0024","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1056\/NEJMoa1009370","article-title":"Outcomes of treatment for hepatitis C virus infection by primary care providers","volume":"364","author":"Arora","year":"2011","journal-title":"N Engl J Med"},{"key":"2020082200571000700_CIT0025","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1742-6405-10-9","article-title":"Increasing hepatitis C treatment uptake among HIV-infected patients using an HIV primary care model","volume":"10","author":"Cachay","year":"2013","journal-title":"AIDS Res Ther"},{"key":"2020082200571000700_CIT0026","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/00333549161310S211","article-title":"Integrating routine HCV testing in primary care: lessons learned from five federally qualified health centers in Philadelphia, Pennsylvania, 2012\u20132014","volume":"131","author":"Coyle","year":"2016","journal-title":"Public Health Rep"},{"key":"2020082200571000700_CIT0027","doi-asserted-by":"crossref","first-page":"311","DOI":"10.7326\/M17-0118","article-title":"Expansion of treatment for hepatitis C virus infection by task shifting to community-based nonspecialist providers: a nonrandomized clinical trial","volume":"167","author":"Kattakuzhy","year":"2017","journal-title":"Ann Intern Med"},{"key":"2020082200571000700_CIT0028","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/jvh.12611","article-title":"Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study","volume":"24","author":"Tapper","year":"2017","journal-title":"J Viral Hepat"},{"key":"2020082200571000700_CIT0029","doi-asserted-by":"crossref","first-page":"e0214795","DOI":"10.1371\/journal.pone.0214795","article-title":"Real-world effectiveness and safety of sofosbuvir\/velpatasvir and ledipasvir\/sofosbuvir hepatitis C treatment in a single centre in Germany","volume":"14","author":"Buggisch","year":"2019","journal-title":"PLoS One"},{"key":"2020082200571000700_CIT0030","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection","volume":"373","author":"Foster","year":"2015","journal-title":"N Engl J Med"},{"key":"2020082200571000700_CIT0031","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa1702417","article-title":"Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection","volume":"378","author":"Zeuzem","year":"2018","journal-title":"N Engl J Med"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciz956\/30706101\/ciz956.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/71\/5\/1263\/33671910\/ciz956.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/71\/5\/1263\/33671910\/ciz956.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,22]],"date-time":"2020-08-22T00:57:32Z","timestamp":1598057852000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/71\/5\/1263\/5575959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,29]]},"references-count":31,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,9,29]]},"published-print":{"date-parts":[[2020,8,22]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciz956","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,9,1]]},"published":{"date-parts":[[2019,9,29]]}}}